{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:41Z","timestamp":1793317601245,"version":"4.5.0"},"reference-count":335,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"Abstract<\/jats:title>\n \n Summary<\/jats:title>\n The National Osteoporosis Guideline Group (NOGG) has updated the revised UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. This guideline is relevant for all healthcare professionals involved in osteoporosis management.<\/jats:p>\n <\/jats:sec>\n \n Introduction<\/jats:title>\n The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013, 2017 and 2021. This paper presents a minor update of the 2021 guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women and men aged 50 years and older.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Where available, systematic reviews, meta-analyses and randomised controlled trials have been used to provide the evidence base. Conclusions and recommendations have been systematically graded according to the strength of the available evidence.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, as well as models of care for fracture prevention. Recommendations are made for training, service leads and commissioners of healthcare, and for review criteria for audit and quality improvement. Specific 2024 updates include guidance on fracture risk assessment by ethnicity, Parkinson\u2019s disease, Down\u2019s syndrome and lower-limb amputation; furthermore, the definition of very high fracture risk has been clarified. Hormone replacement therapy (HRT) is now recommended as a first-line treatment option in younger postmenopausal women with high fracture risk and low baseline risk for adverse events; recommendations regarding abaloparatide are included; additional training resources have been added.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The guideline provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management. This position paper has been endorsed by the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s11657-025-01588-3","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:10:01Z","timestamp":1757355001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["The 2024 UK clinical guideline for the prevention and treatment of osteoporosis"],"prefix":"10.1007","volume":"20","author":[{"given":"Celia L.","family":"Gregson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Avgerinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J. L.","family":"Gittoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Leyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Paskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nic","family":"Vine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Compston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Osteoporosis Guideline Group (NOGG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"1588_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.maturitas.2008.11.022","volume":"62","author":"J Compston","year":"2009","unstructured":"Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105\u2013108","journal-title":"Maturitas"},{"key":"1588_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","volume":"75","author":"J Compston","year":"2013","unstructured":"Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National osteoporosis guideline group (NOGG) update 2013. Maturitas 75:392\u2013396","journal-title":"Maturitas"},{"key":"1588_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43","journal-title":"Arch Osteoporos"},{"key":"1588_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17:58","journal-title":"Arch Osteoporos"},{"key":"1588_CR5","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00198-018-4505-x","volume":"29","author":"NC Harvey","year":"2018","unstructured":"Harvey NC, McCloskey E, Kanis JA, Compston J, Cooper C (2018) Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (technology appraisal 464). Osteoporos Int 29:1511\u20131513","journal-title":"Osteoporos Int"},{"key":"1588_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137\u20131141","journal-title":"J Bone Miner Res"},{"key":"1588_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S8756-3282(01)00614-7","volume":"29","author":"TP van Staa","year":"2001","unstructured":"van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29:517\u2013522","journal-title":"Bone"},{"key":"1588_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstr\u00f6m","year":"2020","unstructured":"Borgstr\u00f6m F, Karlsson L, Orts\u00e4ter G et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15:59","journal-title":"Arch Osteoporos"},{"key":"1588_CR9","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1210\/jc.2004-1568","volume":"90","author":"SA Wainwright","year":"2005","unstructured":"Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES, for the Study of Osteoporotic Fractures Research G (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metabol 90:2787\u20132793","journal-title":"J Clin Endocrinol Metabol"},{"key":"1588_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","volume":"34","author":"SCE Schuit","year":"2004","unstructured":"Schuit SCE, van der Klift M, Weel AEAM, de Laet CEDH, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JPTM, Pols HAP (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 34:195\u2013202","journal-title":"Bone"},{"key":"1588_CR11","doi-asserted-by":"crossref","unstructured":"Kanis JA, Od\u00e9n A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA,\u00a0Fujiwara S,\u00a0Gl\u00fcer C,\u00a0Goltzman D,\u00a0Hans D,\u00a0Krieg MA,\u00a0La Croix A,\u00a0McCloskey E,\u00a0Mellstrom D,\u00a0\u00a0Melton 3rd LJ,\u00a0Pols H,\u00a0Reeve J,\u00a0Sanders K,\u00a0\u00a0Schott AM,\u00a0Silman A, Torgerson D,\u00a0Staa T van,\u00a0Watts NB,\u00a0Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033\u20131046","DOI":"10.1007\/s00198-007-0343-y"},{"key":"1588_CR12","unstructured":"Royal College of Physicians (2019) National hip fracture database annual report. https:\/\/www.nhfd.co.uk\/files\/2019ReportFiles\/NHFD_2019_Annual_Report_v101.pdf"},{"key":"1588_CR13","unstructured":"NHS National Services Scotland (2019) Scottish hip fracture audit. Hip fracture care pathway report 2019. https:\/\/www.shfa.scot.nhs.uk\/Reports\/_docs\/2019-08-20-SHFA-Report.pdf"},{"key":"1588_CR14","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s00198-016-3648-x","volume":"27","author":"UA Al-Sari","year":"2016","unstructured":"Al-Sari UA, Tobias J, Clark E (2016) Health-related quality of life in older people with osteoporotic vertebral fractures: a systematic review and meta-analysis. Osteoporos Int 27:2891\u20132900","journal-title":"Osteoporos Int"},{"key":"1588_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1302\/0301-620X.97B3.35738","volume":"97-b","author":"XL Griffin","year":"2015","unstructured":"Griffin XL, Parsons N, Achten J, Fernandez M, Costa ML (2015) Recovery of health-related quality of life in a United Kingdom hip fracture population. The warwick hip trauma evaluation\u2013a prospective cohort study. Bone Joint J 97-b:372\u2013382","journal-title":"Bone Joint J"},{"key":"1588_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00198-015-3277-9","volume":"27","author":"J Leal","year":"2016","unstructured":"Leal J, Gray AM, Prieto-Alhambra D, Arden NK, Cooper C, Javaid MK, Judge A (2016) Impact of hip fracture on hospital care costs: a population-based study. Osteoporos Int 27:549\u2013558","journal-title":"Osteoporos Int"},{"key":"1588_CR17","doi-asserted-by":"publisher","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, F B (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos doi.org\/https:\/\/doi.org\/10.1007\/s11657-020-00871-9:","DOI":"10.1007\/s11657-020-00871-9"},{"key":"1588_CR18","unstructured":"Royal College of Physicians (2018) National hip fracture database annual report. https:\/\/www.nhfd.co.uk\/files\/2018ReportFiles\/NHFD-2018-Annual-Report-v101.pdf"},{"key":"1588_CR19","volume-title":"The challenge of the next decade: are hip fracture services ready? A review of data from the national hip fracture database (January\u2013December 2019)","author":"Royal College of Physicians","year":"2021","unstructured":"Royal College of Physicians (2021) The challenge of the next decade: are hip fracture services ready? A review of data from the national hip fracture database (January\u2013December 2019). RCP, London"},{"key":"1588_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/ageing\/afv204","volume":"45","author":"S Hawley","year":"2016","unstructured":"Hawley S, Javaid MK, Prieto-Alhambra D, Lippett J, Sheard S, Arden NK, Cooper C, Judge A (2016) Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing 45:236\u2013242","journal-title":"Age Ageing"},{"key":"1588_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521","journal-title":"JAMA"},{"key":"1588_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Od\u00e9n A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, J\u00f6nsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38\u201342","journal-title":"Osteoporos Int"},{"key":"1588_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468\u2013473","journal-title":"Bone"},{"key":"1588_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00198-017-4238-2","volume":"29","author":"A Bhimjiyani","year":"2018","unstructured":"Bhimjiyani A, Neuburger J, Jones T, Ben-Shlomo Y, Gregson CL (2018) The effect of social deprivation on hip fracture incidence in England has not changed over 14 years: an analysis of the English hospital episodes statistics (2001\u20132015). Osteoporos Int 29:115\u2013124","journal-title":"Osteoporos Int"},{"key":"1588_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.puhe.2018.05.002","volume":"162","author":"A Bhimjiyani","year":"2018","unstructured":"Bhimjiyani A, Neuburger J, Jones T, Ben-Shlomo Y, Gregson CL (2018) Inequalities in hip fracture incidence are greatest in the north of England: regional analysis of the effects of social deprivation on hip fracture incidence across England. Public Health 162:25\u201331","journal-title":"Public Health"},{"key":"1588_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bone.2016.03.006","volume":"87","author":"EM Curtis","year":"2016","unstructured":"Curtis EM, van der Velde R, Moon RJ, van den Bergh JP, Geusens P, de Vries F, van Staa TP, Cooper C, Harvey NC (2016) Epidemiology of fractures in the United Kingdom 1988\u20132012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 87:19\u201326","journal-title":"Bone"},{"key":"1588_CR27","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1007\/s00198-016-3650-3","volume":"27","author":"RY van der Velde","year":"2016","unstructured":"van der Velde RY, Wyers CE, Curtis EM, Geusens PPMM, van den Bergh JPW, de Vries F, Cooper C, van Staa TP, Harvey NC (2016) Secular trends in fracture incidence in the UK between 1990 and 2012. Osteoporos Int 27:3197\u20133206","journal-title":"Osteoporos Int"},{"key":"1588_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809\u2013816","journal-title":"Osteoporos Int"},{"key":"1588_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00198-011-1747-2","volume":"23","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Morin S, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75\u201385","journal-title":"Osteoporos Int"},{"key":"1588_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00223-014-9911-2","volume":"95","author":"H Johansson","year":"2014","unstructured":"Johansson H, Kanis JA, Od\u00e9n A et al (2014) Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcified Tiss Inter 95:428\u2013435","journal-title":"Calcified Tiss Inter"},{"key":"1588_CR31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/jbmr.2734","volume":"31","author":"EV McCloskey","year":"2016","unstructured":"McCloskey EV, Od\u00e9n A, Harvey NC et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Mineral Res 31:940\u2013948","journal-title":"J Bone Mineral Res"},{"key":"1588_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jocd.2015.07.004","volume":"19","author":"WD Leslie","year":"2016","unstructured":"Leslie WD, Lix LM, Morin SN, Johansson H, Od\u00e9n A, McCloskey EV, Kanis JA (2016) Adjusting hip fracture probability in men and women using hip axis length: the Manitoba bone density database. J Clin Densitom 19:326\u2013331","journal-title":"J Clin Densitom"},{"key":"1588_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jocd.2011.05.010","volume":"14","author":"T Masud","year":"2011","unstructured":"Masud T, Binkley N, Boonen S, Hannan MT (2011) Official positions for FRAX\u00ae clinical regarding falls and frailty: can falls and frailty be used in FRAX\u00ae? From joint official positions development conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX\u00ae. J Clin Densitom 14:194\u2013204","journal-title":"J Clin Densitom"},{"key":"1588_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00198-023-07012-1","volume":"35","author":"L Vandenput","year":"2024","unstructured":"Vandenput L, Johansson H, McCloskey EV et al (2024) A meta-analysis of previous falls and subsequent fracture risk in cohort studies. Osteoporos Int 35:469\u2013494","journal-title":"Osteoporos Int"},{"key":"1588_CR35","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00198-015-3180-4","volume":"26","author":"H Johansson","year":"2015","unstructured":"Johansson H, Od\u00e9n A, Lorentzon M, McCloskey E, Kanis JA, Harvey NC, Karlsson MK, Mellstr\u00f6m D (2015) Is the Swedish FRAX model appropriate for Swedish immigrants? Osteoporos Int 26:2617\u20132622","journal-title":"Osteoporos Int"},{"key":"1588_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00198-020-05597-5","volume":"32","author":"P W\u00e4ndell","year":"2021","unstructured":"W\u00e4ndell P, Li X, Carlsson AC, Sundquist J, Sundquist K (2021) Osteoporotic fractures among foreign-born individuals: a national Swedish study. Osteoporos Int 32:343\u2013352","journal-title":"Osteoporos Int"},{"key":"1588_CR37","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/jbmr.3538","volume":"33","author":"WD Leslie","year":"2018","unstructured":"Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D (2018) Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD registry. J Bone Miner Res 33:1923\u20131930","journal-title":"J Bone Miner Res"},{"key":"1588_CR38","doi-asserted-by":"publisher","first-page":"116651","DOI":"10.1016\/j.bone.2022.116651","volume":"168","author":"M Schini","year":"2023","unstructured":"Schini M, Bhatia P, Shreef H, Johansson H, Harvey NC, Lorentzon M, Kanis JA, Bandmann O, McCloskey EV (2023) Increased fracture risk in Parkinson\u2019s disease - an exploration of mechanisms and consequences for fracture prediction with FRAX. Bone 168:116651","journal-title":"Bone"},{"key":"1588_CR39","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00198-020-05517-7","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, McCloskey EV (2020) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int 31:1817\u20131828","journal-title":"Osteoporos Int"},{"key":"1588_CR40","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3423","volume":"33","author":"AL Adams","year":"2018","unstructured":"Adams AL, Fischer H, Kopperdahl DL et al (2018) Osteoporosis and hip fracture risk from routine computed tomography scans: the fracture, osteoporosis, and CT utilization study (FOCUS). J Bone Miner Res 33:1291\u20131301","journal-title":"J Bone Miner Res"},{"key":"1588_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11914-018-0450-z","volume":"16","author":"F Johannesdottir","year":"2018","unstructured":"Johannesdottir F, Allaire B, Bouxsein ML (2018) Fracture prediction by computed tomography and finite element analysis: current and future perspectives. Curr Osteoporos Rep 16:411\u2013422","journal-title":"Curr Osteoporos Rep"},{"key":"1588_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jocd.2014.03.002","volume":"18","author":"PJ Pickhardt","year":"2015","unstructured":"Pickhardt PJ, Bodeen G, Brett A, Brown JK, Binkley N (2015) Comparison of femoral neck BMD evaluation obtained using Lunar DXA and QCT with asynchronous calibration from CT colonography. J Clin Densitom 18:5\u201312","journal-title":"J Clin Densitom"},{"key":"1588_CR43","doi-asserted-by":"publisher","first-page":"e91904","DOI":"10.1371\/journal.pone.0091904","volume":"9","author":"CE Cann","year":"2014","unstructured":"Cann CE, Adams JE, Brown JK, Brett AD (2014) CTXA hip\u2013an extension of classical DXA measurements using quantitative CT. PLoS ONE 9:e91904\u2013e91904","journal-title":"PLoS ONE"},{"key":"1588_CR44","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/jbmr.2856","volume":"31","author":"TJ Ziemlewicz","year":"2016","unstructured":"Ziemlewicz TJ, Maciejewski A, Binkley N, Brett AD, Brown JK, Pickhardt PJ (2016) Opportunistic quantitative CT bone mineral density measurement at the proximal femur using routine contrast-enhanced scans: direct comparison with DXA in 355 adults. J Bone Miner Res 31:1835\u20131840","journal-title":"J Bone Miner Res"},{"key":"1588_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-018-0784-7","volume":"20","author":"L Lenchik","year":"2018","unstructured":"Lenchik L, Weaver AA, Ward RJ, Boone JM, Boutin RD (2018) Opportunistic screening for osteoporosis using computed tomography: state of the art and argument for paradigm shift. Curr Rheumatol Rep 20:74","journal-title":"Curr Rheumatol Rep"},{"key":"1588_CR46","unstructured":"Kanis JA, on behalf of the WHO Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical report. WHO Collaborating Centre, University of Sheffield, UK, Sheffield 2008"},{"key":"1588_CR47","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","volume":"16","author":"C Laet","year":"2005","unstructured":"Laet C, Kanis J, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330\u20131338","journal-title":"Osteoporos Int"},{"key":"1588_CR48","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00198-019-05274-2","volume":"31","author":"WD Leslie","year":"2020","unstructured":"Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix LM, Johansson H, McCloskey EV, Harvey NC, Kanis JA (2020) Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. Osteoporos Int 31:1059\u20131067","journal-title":"Osteoporos Int"},{"key":"1588_CR49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375\u2013382","journal-title":"Bone"},{"key":"1588_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00198-013-2460-0","volume":"25","author":"H Johansson","year":"2014","unstructured":"Johansson H, Od\u00e9n A, McCloskey EV, Kanis JA (2014) Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporos Int 25:235\u2013241","journal-title":"Osteoporos Int"},{"key":"1588_CR51","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Od\u00e9n A et al (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747\u20131757","journal-title":"Osteoporos Int"},{"key":"1588_CR52","unstructured":"Excellence. NIfHaC (2019) NICE guideline [NG132]: hyperparathyroidism (primary): diagnosis, assessment and initial management. https:\/\/www.nice.org.uk\/guidance\/ng132\/chapter\/Recommendations#diagnostic-testing-in-primary-care"},{"key":"1588_CR53","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A et al (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029\u20131037","journal-title":"Bone"},{"issue":"2","key":"1588_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16(2):155\u2013162","journal-title":"Osteoporos Int"},{"key":"1588_CR55","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP van Staa","year":"2000","unstructured":"van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383\u20131389","journal-title":"Rheumatology (Oxford)"},{"key":"1588_CR56","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1359\/JBMR.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Mineral Research 19:893\u2013899","journal-title":"J Bone Mineral Research"},{"key":"1588_CR57","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00198-004-1734-y","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737\u2013742","journal-title":"Osteoporos Int"},{"key":"1588_CR58","doi-asserted-by":"publisher","first-page":"115457","DOI":"10.1016\/j.bone.2020.115457","volume":"137","author":"T Vilaca","year":"2020","unstructured":"Vilaca T, Schini M, Harnan S, Sutton A, Poku E, Allen IE, Cummings SR, Eastell R (2020) The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update. Bone 137:115457","journal-title":"Bone"},{"key":"1588_CR59","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s40520-019-01417-x","volume":"32","author":"J Bai","year":"2020","unstructured":"Bai J, Gao Q, Wang C, Dai J (2020) Diabetes mellitus and risk of low-energy fracture: a meta-analysis. Aging Clin Exp Res 32:2173\u20132186","journal-title":"Aging Clin Exp Res"},{"issue":"11","key":"1588_CR60","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1002\/jbmr.1759","volume":"27","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Rubin MR, Schwartz AV, Kanis JA (2012) Type 2 diabetes and bone. J Bone Miner Res 27(11):2231\u20137. https:\/\/doi.org\/10.1002\/jbmr.1759","journal-title":"J Bone Miner Res"},{"key":"1588_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jbmr.556","volume":"27","author":"LM Giangregorio","year":"2012","unstructured":"Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27:301\u2013308","journal-title":"J Bone Miner Res"},{"key":"1588_CR62","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s00198-009-0845-x","volume":"20","author":"H Johansson","year":"2009","unstructured":"Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20:1675\u20131682","journal-title":"Osteoporos Int"},{"key":"1588_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-011-9544-7","volume":"90","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX(\u00ae) with and without bone mineral density. Calcif Tissue Int 90:1\u201313","journal-title":"Calcif Tissue Int"},{"key":"1588_CR64","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Hip intervention program study group et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"1588_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-020-00688-1","volume":"107","author":"SJ Mortensen","year":"2020","unstructured":"Mortensen SJ, Mohamadi A, Wright CL, Chan JJ, Weaver MJ, von Keudell A, Nazarian A (2020) Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis. Calcif Tissue Int 107:1\u20139","journal-title":"Calcif Tissue Int"},{"key":"1588_CR66","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00223-007-9065-6","volume":"81","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int 81:153\u2013161","journal-title":"Calcif Tissue Int"},{"key":"1588_CR67","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00198-010-1455-3","volume":"22","author":"ME Arbouw","year":"2011","unstructured":"Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F (2011) Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporos Int 22:2197\u20132204","journal-title":"Osteoporos Int"},{"key":"1588_CR68","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.3346\/jkms.2020.35.e403","volume":"35","author":"YK Lee","year":"2020","unstructured":"Lee YK, Lee EG, Kim HY, Lee Y, Lee SM, Suh DC, Yoo JI, Lee S (2020) Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis. J Korean Med Sci 35:e403","journal-title":"J Korean Med Sci"},{"key":"1588_CR69","doi-asserted-by":"publisher","first-page":"e2025826","DOI":"10.1001\/jamanetworkopen.2020.25826","volume":"3","author":"ZW Myint","year":"2020","unstructured":"Myint ZW, Momo HD, Otto DE, Yan D, Wang P, Kolesar JM (2020) Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis. JAMA Netw Open 3:e2025826","journal-title":"JAMA Netw Open"},{"key":"1588_CR70","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1210\/jc.2014-1971","volume":"99","author":"F Cosman","year":"2014","unstructured":"Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM (2014) Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab 99:4546\u20134554","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR71","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s00198-015-3123-0","volume":"26","author":"A Palermo","year":"2015","unstructured":"Palermo A, D\u2019Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N (2015) Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int 26:2073\u20132089","journal-title":"Osteoporos Int"},{"key":"1588_CR72","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1210\/jc.2017-01642","volume":"102","author":"N Singh-Ospina","year":"2017","unstructured":"Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, Davidge-Pitts C, Nippoldt TB, Prokop LJ, Murad MH (2017) Effect of sex steroids on the bone health of transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab 102:3904\u20133913","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR73","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23:2769\u20132774","journal-title":"Osteoporos Int"},{"key":"1588_CR74","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","volume":"36","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M, Branco J, Brandi ML et al (2019) Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther 36:2811\u20132824","journal-title":"Adv Ther"},{"key":"1588_CR75","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","volume":"94","author":"H Johansson","year":"2014","unstructured":"Johansson H, Od\u00e9n A, Kanis JA, McCloskey EV, Morris HA, Cooper C, Vasikaran S (2014) A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int 94:560\u2013567","journal-title":"Calcif Tissue Int"},{"key":"1588_CR76","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00198-020-05700-w","volume":"32","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC et al (2021) The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. Osteoporos Int 32:47\u201354","journal-title":"Osteoporos Int"},{"issue":"6","key":"1588_CR77","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00198-021-05962-y","volume":"32","author":"EV McCloskey","year":"2021","unstructured":"McCloskey EV, Borgstr\u00f6m F, Cooper C, Harvey NC, Javaid MK, Lorentzon M, Kanis JA (2021) Short time horizons for fracture prediction tools: time for a rethink. Osteoporos Int 32(6):1019\u20131025. https:\/\/doi.org\/10.1007\/s00198-021-05962-y","journal-title":"Osteoporos Int"},{"key":"1588_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Od\u00e9n A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25","journal-title":"Arch Osteoporos"},{"key":"1588_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4229","author":"J Hippisley-Cox","year":"2009","unstructured":"Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. https:\/\/doi.org\/10.1136\/bmj.b4229","journal-title":"BMJ"},{"key":"1588_CR80","unstructured":"National Institute for Health and Care Excellence (2012) Osteoporosis: assessing the risk of fragility fracture. NICE clinical guideline [CG146]. Manchester: NICE. http:\/\/www.nice.org.uk\/guidance\/cg146"},{"key":"1588_CR81","unstructured":"National Institute for Health and Care Excellence (NICE) (2017) Osteoporosis: quality standard [QS149]. Manchester, NICE. https:\/\/www.nice.org.uk\/guidance\/qs149"},{"key":"1588_CR82","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1359\/jbmr.1998.13.10.1587","volume":"13","author":"CE De Laet","year":"1998","unstructured":"De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1998) Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 13:1587\u20131593","journal-title":"J Bone Miner Res"},{"key":"1588_CR83","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11914-014-0242-z","volume":"12","author":"N Binkley","year":"2014","unstructured":"Binkley N, Adler R, Bilezikian JP (2014) Osteoporosis diagnosis in men: the T-score controversy revisited. Curr Osteoporos Rep 12:403\u2013409","journal-title":"Curr Osteoporos Rep"},{"key":"1588_CR84","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00198-020-05776-4","volume":"32","author":"P W\u00e4ndell","year":"2021","unstructured":"W\u00e4ndell P, Li X, Carlsson AC, Sundquist J, Sundquist K (2021) Osteoporotic fractures in second-generation immigrants and Swedish natives. Osteoporos Int 32:1343\u20131350","journal-title":"Osteoporos Int"},{"key":"1588_CR85","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00198-005-0014-9","volume":"17","author":"JA Kanis","year":"2006","unstructured":"Kanis JA, Johnell O, Oden A et al (2006) The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int 17:527\u2013534","journal-title":"Osteoporos Int"},{"key":"1588_CR86","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1359\/jbmr.061112","volume":"22","author":"WD Leslie","year":"2007","unstructured":"Leslie WD, Tsang JF, Caetano PA, Lix LM (2007) Number of osteoporotic sites and fracture risk assessment: a cohort study from the Manitoba bone density program. J Bone Miner Res 22:476\u2013483","journal-title":"J Bone Miner Res"},{"key":"1588_CR87","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00198-019-04975-y","volume":"30","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Martineau P, Bryanton M, Lix LM (2019) Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study. Osteoporos Int 30:1445\u20131453","journal-title":"Osteoporos Int"},{"key":"1588_CR88","unstructured":"Royal Osteoporosis Society (2019) Reporting dual energy X-ray absorptiometry scans in adult fracture risk assessment: standards for quality. https:\/\/theros.org.uk\/media\/xhfhyy52\/ros-reporting-dxa-scans-in-adult-fracture-risk-assessment-august-2019.pdf"},{"key":"1588_CR89","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254\u20131259","journal-title":"BMJ"},{"key":"1588_CR90","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185\u20131194","journal-title":"J Bone Miner Res"},{"key":"1588_CR91","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","volume":"359","author":"JA Kanis","year":"2002","unstructured":"Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929\u20131936","journal-title":"Lancet"},{"key":"1588_CR92","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s001980050281","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors. Int Osteoporo Found Osteoporos Int 11:192\u2013202","journal-title":"Int Osteoporo Found Osteoporos Int"},{"key":"1588_CR93","doi-asserted-by":"publisher","first-page":"115173","DOI":"10.1016\/j.bone.2019.115173","volume":"132","author":"M Schini","year":"2020","unstructured":"Schini M, Vilaca T, Poku E, Harnan S, Sutton A, Allen IE, Cummings SR, Eastell R (2020) The risk of hip and non-vertebral fractures in patients with Parkinson\u2019s disease and parkinsonism: a systematic review and meta-analysis. Bone 132:115173","journal-title":"Bone"},{"key":"1588_CR94","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00198-013-2525-0","volume":"25","author":"SL Brennan","year":"2014","unstructured":"Brennan SL, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2014) FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos Int 25:61\u201369","journal-title":"Osteoporos Int"},{"key":"1588_CR95","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1002\/jbmr.2280","volume":"29","author":"WD Leslie","year":"2014","unstructured":"Leslie WD, Orwoll ES, Nielson CM, Morin SN, Majumdar SR, Johansson H, Od\u00e9n A, McCloskey EV, Kanis JA (2014) Estimated lean mass and fat mass differentially affect femoral bone density and strength index but are not FRAX independent risk factors for fracture. J Bone Miner Res 29:2511\u20132519","journal-title":"J Bone Miner Res"},{"key":"1588_CR96","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4318","author":"C Ye","year":"2024","unstructured":"Ye C, Leslie WD, Al-Azazi S et al (2024) Fracture risk prediction using the fracture risk assessment tool in individuals with cancer. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4318","journal-title":"JAMA Oncol"},{"key":"1588_CR97","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.kint.2018.09.022","volume":"95","author":"RH Whitlock","year":"2019","unstructured":"Whitlock RH, Leslie WD, Shaw J, Rigatto C, Thorlacius L, Komenda P, Collister D, Kanis JA, Tangri N (2019) The fracture risk assessment tool (FRAX\u00ae) predicts fracture risk in patients with chronic kidney disease. Kidney Int 95:447\u2013454","journal-title":"Kidney Int"},{"key":"1588_CR98","volume-title":"Communicating risks and benefits: an evidence-based user\u2019s guide","author":"B Fischhoff","year":"2018","unstructured":"Fischhoff B, Brewer Noel T, Downs JS (2018) Communicating risks and benefits: an evidence-based user\u2019s guide. US Department of Health and Human Services Food and Drug Administration, US"},{"key":"1588_CR99","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1359\/JBMR.050314","volume":"20","author":"HA Fink","year":"2005","unstructured":"Fink HA, Milavetz DL, Palermo L, Nevitt MC, Cauley JA, Genant HK, Black DM, Ensrud KE (2005) What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 20:1216\u20131222","journal-title":"J Bone Miner Res"},{"key":"1588_CR100","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s001980050218","volume":"10","author":"LJ Melton 3rd","year":"1999","unstructured":"Melton LJ 3rd, Atkinson EJ, Cooper C, O\u2019Fallon WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214\u2013221","journal-title":"Osteoporos Int"},{"key":"1588_CR101","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2001","unstructured":"Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320\u2013323","journal-title":"JAMA"},{"key":"1588_CR102","doi-asserted-by":"publisher","first-page":"898","DOI":"10.31616\/asj.2020.0594","volume":"14","author":"HD Jang","year":"2020","unstructured":"Jang HD, Kim EH, Lee JC, Choi SW, Kim K, Shin BJ (2020) Current concepts in the management of osteoporotic vertebral fractures: a narrative review. Asian Spine J 14:898\u2013909","journal-title":"Asian Spine J"},{"key":"1588_CR103","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11914-010-0018-z","volume":"8","author":"EM Lewiecki","year":"2010","unstructured":"Lewiecki EM (2010) Bone densitometry and vertebral fracture assessment. Curr Osteoporos Rep 8:123\u2013130","journal-title":"Curr Osteoporos Rep"},{"key":"1588_CR104","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2106\/JBJS.16.00749","volume":"99","author":"EB Gausden","year":"2017","unstructured":"Gausden EB, Nwachukwu BU, Schreiber JJ, Lorich DG, Lane JM (2017) Opportunistic use of CT imaging for osteoporosis screening and bone density assessment: a qualitative systematic review. J Bone Joint Surg Am 99:1580\u20131590","journal-title":"J Bone Joint Surg Am"},{"key":"1588_CR105","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/jbmr.4205","volume":"35","author":"PA Bromiley","year":"2020","unstructured":"Bromiley PA, Clark EM, Poole KE (2020) Computer-aided diagnostic systems for osteoporotic vertebral fracture detection: opportunities and challenges. J Bone Miner Res 35:2305\u20132306","journal-title":"J Bone Miner Res"},{"key":"1588_CR106","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/jbmr.4146","volume":"35","author":"N Kolanu","year":"2020","unstructured":"Kolanu N, Silverstone EJ, Ho BH, Pham H, Hansen A, Pauley E, Quirk AR, Sweeney SC, Center JR, Pocock NA (2020) Clinical utility of computer-aided diagnosis of vertebral fractures from computed tomography images. J Bone Miner Res 35:2307\u20132312","journal-title":"J Bone Miner Res"},{"key":"1588_CR107","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1007\/s00330-020-06845-2","volume":"30","author":"DC Howlett","year":"2020","unstructured":"Howlett DC, Drinkwater KJ, Mahmood N, Illes J, Griffin J, Javaid K (2020) Radiology reporting of osteoporotic vertebral fragility fractures on computed tomography studies: results of a UK national audit. Eur Radiol 30:4713\u20134723","journal-title":"Eur Radiol"},{"key":"1588_CR108","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00198-011-1774-z","volume":"23","author":"YM Kim","year":"2012","unstructured":"Kim YM, Demissie S, Genant HK, Cheng X, Yu W, Samelson EJ, Kiel DP, Bouxsein ML (2012) Identification of prevalent vertebral fractures using CT lateral scout views: a comparison of semi-automated quantitative vertebral morphometry and radiologist semi-quantitative grading. Osteoporos Int 23:1007\u20131016","journal-title":"Osteoporos Int"},{"key":"1588_CR109","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-017-4326-3","volume":"29","author":"KH Rubin","year":"2018","unstructured":"Rubin KH, Rothmann MJ, Holmberg T et al (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized risk-stratified osteoporosis strategy evaluation (ROSE) study. Osteoporos Int 29:567\u2013578","journal-title":"Osteoporos Int"},{"key":"1588_CR110","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/jbmr.3815","volume":"34","author":"T Merlijn","year":"2019","unstructured":"Merlijn T, Swart KM, van Schoor NM et al (2019) The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res 34:1993\u20132000","journal-title":"J Bone Miner Res"},{"key":"1588_CR111","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-019-05226-w","volume":"31","author":"T Merlijn","year":"2020","unstructured":"Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM (2020) Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 31:251\u2013257","journal-title":"Osteoporos Int"},{"key":"1588_CR112","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s001980050138","volume":"9","author":"AA Ismail","year":"1999","unstructured":"Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ, O\u2019Neill TW (1999) Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral osteoporosis study group. Osteoporos Int 9:206\u2013213","journal-title":"Osteoporos Int"},{"key":"1588_CR113","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ijsu.2020.01.018","volume":"75","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Dong J, Zhou D, Liu F (2020) Comparative risk of fracture for bariatric procedures in patients with obesity: a systematic review and Bayesian network meta-analysis. Int J Surg (London, England) 75:13\u201323","journal-title":"Int J Surg (London, England)"},{"key":"1588_CR114","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX\u2013assessment and intervention thresholds for the UK. Osteoporos Int 19:1395\u20131408","journal-title":"Osteoporos Int"},{"key":"1588_CR115","unstructured":"National Institute for Health and Care Excellence (2019) Bisphosphonates for treating osteoporosis. Technology appraisal guidance [TA464]. https:\/\/www.nice.org.uk\/guidance\/ta464"},{"key":"1588_CR116","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00198-015-3176-0","volume":"26","author":"E McCloskey","year":"2015","unstructured":"McCloskey E, Kanis JA, Johansson H et al (2015) FRAX-based assessment and intervention thresholds\u2013an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091\u20132099","journal-title":"Osteoporos Int"},{"key":"1588_CR117","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","volume":"391","author":"L Shepstone","year":"2018","unstructured":"Shepstone L, Lenaghan E, Cooper C et al (2018) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391:741\u2013747","journal-title":"Lancet"},{"key":"1588_CR118","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"1588_CR119","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1588_CR120","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240","journal-title":"Lancet"},{"key":"1588_CR121","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722\u2013733","journal-title":"JAMA"},{"key":"1588_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312","journal-title":"Osteoporos Int"},{"key":"1588_CR123","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","volume":"33","author":"PD Delmas","year":"2003","unstructured":"Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522\u2013532","journal-title":"Bone"},{"key":"1588_CR124","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"1588_CR125","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s001980170131","volume":"12","author":"O Johnell","year":"2001","unstructured":"Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12:207\u2013214","journal-title":"Osteoporos Int"},{"key":"1588_CR126","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/jbmr.35","volume":"25","author":"LM Giangregorio","year":"2010","unstructured":"Giangregorio LM, Leslie WD (2010) Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25:1400\u20131405","journal-title":"J Bone Miner Res"},{"key":"1588_CR127","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s002239900446","volume":"62","author":"KE Dretakis","year":"1998","unstructured":"Dretakis KE, Dretakis EK, Papakitsou EF, Psarakis S, Steriopoulos K (1998) Possible predisposing factors for the second hip fracture. Calcif Tissue Int 62:366\u2013369","journal-title":"Calcif Tissue Int"},{"key":"1588_CR128","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00198-006-0125-y","volume":"17","author":"T Nymark","year":"2006","unstructured":"Nymark T, Lauritsen JM, Ovesen O, R\u00f6ck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County hip fracture study. Osteoporos Int 17:1353\u20131357","journal-title":"Osteoporos Int"},{"key":"1588_CR129","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1359\/jbmr.090207","volume":"24","author":"J Ryg","year":"2009","unstructured":"Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977\u20132001. J Bone Miner Res 24:1299\u20131307","journal-title":"J Bone Miner Res"},{"key":"1588_CR130","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/ard.2008.092775","volume":"68","author":"TA van Geel","year":"2009","unstructured":"van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99\u2013102","journal-title":"Ann Rheum Dis"},{"key":"1588_CR131","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775\u2013780","journal-title":"Osteoporos Int"},{"key":"1588_CR132","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05803-4","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, McCloskey EV (2021) The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-020-05803-4","journal-title":"Osteoporos Int"},{"key":"1588_CR133","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00198-020-05463-4","volume":"31","author":"JJ Body","year":"2020","unstructured":"Body JJ, Marin F, Kendler DL et al (2020) Efficacy of teriparatide compared with risedronate on FRAX(\u00ae)-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 31:1935\u20131942","journal-title":"Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"key":"1588_CR134","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"1588_CR135","doi-asserted-by":"publisher","unstructured":"Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, EV. M (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines. Osteoporos Int https:\/\/doi.org\/10.1007\/s00198-00021-05942-00192","DOI":"10.1007\/s00198-00021-05942-00192"},{"key":"1588_CR136","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00223-014-9844-9","volume":"94","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Rizzoli R, Cooper C, Reginster JY (2014) Challenges for the development of bone-forming agents in Europe. Calcif Tissue Int 94:469\u2013473","journal-title":"Calcif Tissue Int"},{"key":"1588_CR137","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00198-011-1864-y","volume":"23","author":"H Johansson","year":"2012","unstructured":"Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907\u2013915","journal-title":"Osteoporos Int"},{"key":"1588_CR138","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"1588_CR139","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1210\/jc.2008-2765","volume":"94","author":"R Eastell","year":"2009","unstructured":"Eastell R, Black DM, Boonen S et al (2009) Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94:3215\u20133225","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR140","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00198-015-3129-7","volume":"26","author":"NC Harvey","year":"2015","unstructured":"Harvey NC, Kanis JA, Od\u00e9n A, Nakamura T, Shiraki M, Sugimoto T, Kuroda T, Johansson H, McCloskey EV (2015) Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int 26:2347\u20132353","journal-title":"Osteoporos Int"},{"key":"1588_CR141","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00198-015-3406-5","volume":"27","author":"E McCloskey","year":"2016","unstructured":"McCloskey E (2016) A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporos Int 27:417\u2013419","journal-title":"Osteoporos Int"},{"key":"1588_CR142","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD (2018) Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 379:2407\u20132416","journal-title":"N Engl J Med"},{"key":"1588_CR143","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jbmr.2991","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM (2017) Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res 32:17\u201323","journal-title":"J Bone Miner Res"},{"key":"1588_CR144","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/jbmr.3163","volume":"32","author":"EV McCloskey","year":"2017","unstructured":"McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA (2017) The effect of abaloparatide-sc on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res 32:1625\u20131631","journal-title":"J Bone Miner Res"},{"key":"1588_CR145","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1359\/jbmr.2004.19.6.906","volume":"19","author":"H Johansson","year":"2004","unstructured":"Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment\u2013a test analysis. J Bone Mineral Res 19:906\u2013913","journal-title":"J Bone Mineral Res"},{"key":"1588_CR146","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-011-1592-3","volume":"23","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23:391\u2013397","journal-title":"Osteoporos Int"},{"key":"1588_CR147","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jbmr.1582","volume":"27","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243\u20131251","journal-title":"J Bone Miner Res"},{"key":"1588_CR148","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/advances\/nmy073","volume":"10","author":"R Fabiani","year":"2019","unstructured":"Fabiani R, Naldini G, Chiavarini M (2019) Dietary patterns in relation to low bone mineral density and fracture risk: a systematic review and meta-analysis. Advances in nutrition (Bethesda, Md) 10:219\u2013236","journal-title":"Advances in nutrition (Bethesda, Md)"},{"key":"1588_CR149","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1093\/jn\/133.10.3130","volume":"133","author":"P-H Lin","year":"2003","unstructured":"Lin P-H, Ginty F, Appel LJ, Aickin M, Bohannon A, Garnero P, Barclay D, Svetkey LP (2003) The DASH diet and sodium reduction improve markers of bone turnover and calcium metabolism in adults. J Nutr 133:3130\u20133136","journal-title":"J Nutr"},{"key":"1588_CR150","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.csbj.2019.07.005","volume":"17","author":"I Groenendijk","year":"2019","unstructured":"Groenendijk I, den Boeft L, van Loon LJC, de Groot L (2019) High versus low dietary protein intake and bone health in older adults: a systematic review and meta-analysis. Comput Struct Biotechnol J 17:1101\u20131112","journal-title":"Comput Struct Biotechnol J"},{"key":"1588_CR151","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00198-019-04933-8","volume":"30","author":"AL Darling","year":"2019","unstructured":"Darling AL, Manders RJF, Sahni S, Zhu K, Hewitt CE, Prince RL, Millward DJ, Lanham-New SA (2019) Dietary protein and bone health across the life-course: an updated systematic review and meta-analysis over 40 years. Osteoporos Int 30:741\u2013761","journal-title":"Osteoporos Int"},{"key":"1588_CR152","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ageing\/afs078","volume":"42","author":"MW Myint","year":"2013","unstructured":"Myint MW, Wu J, Wong E, Chan SP, To TS, Chau MW, Ting KH, Fung PM, Au KS (2013) Clinical benefits of oral nutritional supplementation for elderly hip fracture patients: a single blind randomised controlled trial. Age Ageing 42:39\u201345","journal-title":"Age Ageing"},{"key":"1588_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nutrit\/nuy045","volume":"77","author":"I Iguacel","year":"2019","unstructured":"Iguacel I, Miguel-Berges ML, G\u00f3mez-Bruton A, Moreno LA, Juli\u00e1n C (2019) Veganism, vegetarianism, bone mineral density, and fracture risk: a systematic review and meta-analysis. Nutr Rev 77:1\u201318","journal-title":"Nutr Rev"},{"key":"1588_CR154","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12916-020-01815-3","volume":"18","author":"TYN Tong","year":"2020","unstructured":"Tong TYN, Appleby PN, Armstrong MEG, Fensom GK, Knuppel A, Papier K, Perez-Cornago A, Travis RC, Key TJ (2020) Vegetarian and vegan diets and risks of total and site-specific fractures: results from the prospective EPIC-Oxford study. BMC Med 18:353","journal-title":"BMC Med"},{"key":"1588_CR155","volume-title":"Dietary reference values for food energy and nutrients for the United Kingdom","author":"Department of Health","year":"1991","unstructured":"Department of Health (1991) Dietary reference values for food energy and nutrients for the United Kingdom. HMSO, London"},{"key":"1588_CR156","unstructured":"Scientific Advisory Committee on Nutrition (SACN) (2016) Vitamin D and Health. https:\/\/www.gov.uk\/government\/groups\/scientific-advisory-committee-on-nutrition"},{"key":"1588_CR157","unstructured":"Royal Osteoporosis Society (2018) Vitamin D and bone health: a practical clinical guideline for patient management. https:\/\/strwebprdmedia.blob.core.windows.net\/media\/ef2ideu2\/ros-vitamin-d-and-bone-health-in-adults-february-2020.pdf"},{"key":"1588_CR158","doi-asserted-by":"publisher","first-page":"e1917789","DOI":"10.1001\/jamanetworkopen.2019.17789","volume":"2","author":"P Yao","year":"2019","unstructured":"Yao P, Bennett D, Mafham M, Lin X, Chen Z, Armitage J, Clarke R (2019) Vitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis. JAMA Netw Open 2:e1917789","journal-title":"JAMA Netw Open"},{"key":"1588_CR159","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","volume":"370","author":"BM Tang","year":"2007","unstructured":"Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657\u2013666","journal-title":"Lancet"},{"key":"1588_CR160","doi-asserted-by":"publisher","first-page":"b5463","DOI":"10.1136\/bmj.b5463","volume":"340","author":"Group. DVDIPAoRT","year":"2010","unstructured":"Group. DVDIPAoRT (2010) Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340:b5463","journal-title":"BMJ"},{"key":"1588_CR161","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00198-016-3773-6","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, Biver E, Kaufman JM et al (2017) The role of calcium supplementation in healthy musculoskeletal ageing. Osteoporos Int 28:447\u2013462","journal-title":"Osteoporos Int"},{"key":"1588_CR162","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2017.21640","volume":"319","author":"LC Kahwati","year":"2018","unstructured":"Kahwati LC, Weber RP, Pan H, Gourlay M, LeBlanc E, Coker-Schwimmer M, Viswanathan M (2018) Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: evidence report and systematic review for the US preventive services task force. JAMA 319:1600\u20131612","journal-title":"JAMA"},{"key":"1588_CR163","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1001\/jama.2010.594","volume":"303","author":"KM Sanders","year":"2010","unstructured":"Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303:1815\u20131822","journal-title":"JAMA"},{"key":"1588_CR164","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jamainternmed.2015.7148","volume":"176","author":"HA Bischoff-Ferrari","year":"2016","unstructured":"Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, Dick W, Willett WC, Egli A (2016) Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med 176:175\u2013183","journal-title":"JAMA Intern Med"},{"issue":"7","key":"1588_CR165","doi-asserted-by":"publisher","first-page":"Cd000333","DOI":"10.1002\/14651858.CD000333.pub2","volume":"6","author":"TE Howe","year":"2011","unstructured":"Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 6(7):Cd000333. https:\/\/doi.org\/10.1002\/14651858.CD000333.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1588_CR166","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00223-020-00744-w","volume":"107","author":"W Kemmler","year":"2020","unstructured":"Kemmler W, Shojaa M, Kohl M, von Stengel S (2020) Effects of different types of exercise on bone mineral density in postmenopausal women: a systematic review and meta-analysis. Calcif Tissue Int 107:409\u2013439","journal-title":"Calcif Tissue Int"},{"key":"1588_CR167","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.apmr.2019.07.007","volume":"101","author":"OO Babatunde","year":"2020","unstructured":"Babatunde OO, Bourton AL, Hind K, Paskins Z, Forsyth JJ (2020) Exercise interventions for preventing and treating low bone mass in the forearm: a systematic review and meta-analysis. Arch Phys Med Rehabil 101:487\u2013511","journal-title":"Arch Phys Med Rehabil"},{"key":"1588_CR168","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bone.2012.11.031","volume":"53","author":"GA Kelley","year":"2013","unstructured":"Kelley GA, Kelley KS, Kohrt WM (2013) Exercise and bone mineral density in men: a meta-analysis of randomized controlled trials. Bone 53:103\u2013111","journal-title":"Bone"},{"key":"1588_CR169","unstructured":"Royal Osteoporosis Society (2018) Strong, steady and straight; an expert consensus statement on physical activity and exercise for osteoporosis. https:\/\/theros.org.uk\/media\/0o5h1l53\/ros-strong-steady-straight-quick-guide-february-2019.pdf"},{"key":"1588_CR170","doi-asserted-by":"publisher","first-page":"155","DOI":"10.22540\/JFSF-03-155","volume":"3","author":"SK Kunutsor","year":"2018","unstructured":"Kunutsor SK, Leyland S, Skelton DA, James L, Cox M, Gibbons N, Whitney J, Clark EM (2018) Adverse events and safety issues associated with physical activity and exercise for adults with osteoporosis and osteopenia: a systematic review of observational studies and an updated review of interventional studies. J Frailty Sarcopenia Falls 3:155\u2013178","journal-title":"J Frailty Sarcopenia Falls"},{"key":"1588_CR171","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2002183","volume":"383","author":"S Bhasin","year":"2020","unstructured":"Bhasin S, Gill TM, Reuben DB et al (2020) A randomized trial of a multifactorial strategy to prevent serious fall injuries. N Engl J Med 383:129\u2013140","journal-title":"N Engl J Med"},{"key":"1588_CR172","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1056\/NEJMoa2001500","volume":"383","author":"SE Lamb","year":"2020","unstructured":"Lamb SE, Bruce J, Hossain A et al (2020) Screening and intervention to prevent falls and fractures in older people. N Engl J Med 383:1848\u20131859","journal-title":"N Engl J Med"},{"key":"1588_CR173","doi-asserted-by":"publisher","first-page":"f6234","DOI":"10.1136\/bmj.f6234","volume":"347","author":"F El-Khoury","year":"2013","unstructured":"El-Khoury F, Cassou B, Charles M-A, Dargent-Molina P (2013) The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials. BMJ 347:f6234. https:\/\/doi.org\/10.1136\/bmj.f6234","journal-title":"BMJ"},{"key":"1588_CR174","first-page":"Cd012424","volume":"1","author":"C Sherrington","year":"2019","unstructured":"Sherrington C, Fairhall NJ, Wallbank GK, Tiedemann A, Michaleff ZA, Howard K, Clemson L, Hopewell S, Lamb SE (2019) Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev 1:Cd012424","journal-title":"Cochrane Database Syst Rev"},{"key":"1588_CR175","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12877-019-1359-9","volume":"19","author":"R Zhao","year":"2019","unstructured":"Zhao R, Bu W, Chen X (2019) The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions, and differing intervention protocols: a meta-analysis of randomized controlled trials. BMC Geriatr 19:341","journal-title":"BMC Geriatr"},{"key":"1588_CR176","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/bjsports-2016-096547","volume":"51","author":"C Sherrington","year":"2017","unstructured":"Sherrington C, Michaleff ZA, Fairhall N, Paul SS, Tiedemann A, Whitney J, Cumming RG, Herbert RD, Close JCT, Lord SR (2017) Exercise to prevent falls in older adults: an updated systematic review and meta-analysis. Br J Sports Med 51:1750\u20131758","journal-title":"Br J Sports Med"},{"issue":"9","key":"1588_CR177","doi-asserted-by":"publisher","first-page":"CD007146","DOI":"10.1002\/14651858.CD007146.pub3","volume":"2012","author":"LD Gillespie","year":"2012","unstructured":"Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012(9):CD007146. https:\/\/doi.org\/10.1002\/14651858.CD007146.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1588_CR178","doi-asserted-by":"publisher","first-page":"e018342","DOI":"10.1136\/bmjopen-2017-018342","volume":"7","author":"DB Jepsen","year":"2017","unstructured":"Jepsen DB, Thomsen K, Hansen S, J\u00f8rgensen NR, Masud T, Ryg J (2017) Effect of whole-body vibration exercise in preventing falls and fractures: a systematic review and meta-analysis. BMJ Open 7:e018342","journal-title":"BMJ Open"},{"key":"1588_CR179","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00198-015-3290-z","volume":"27","author":"MH Thorin","year":"2016","unstructured":"Thorin MH, Wihlborg A, \u00c5kesson K, Gerdhem P (2016) Smoking, smoking cessation, and fracture risk in elderly women followed for 10 years. Osteoporos Int 27:249\u2013255","journal-title":"Osteoporos Int"},{"key":"1588_CR180","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.injury.2015.04.008","volume":"46","author":"GS Shen","year":"2015","unstructured":"Shen GS, Li Y, Zhao G, Zhou HB, Xie ZG, Xu W, Chen HN, Dong QR, Xu YJ (2015) Cigarette smoking and risk of hip fracture in women: a meta-analysis of prospective cohort studies. Injury 46:1333\u20131340","journal-title":"Injury"},{"key":"1588_CR181","first-page":"1883","volume":"28","author":"W Min","year":"2017","unstructured":"Min W, An R, Li S, Feng J, Yang J, Huang Z (2017) The effects of preoperative smoking cessation on the healing of fractures and postoperative complications: a systematic review and meta-analysis. Biomed Res 28:1883\u20131889","journal-title":"Biomed Res"},{"key":"1588_CR182","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.ajmo.2021.100002","volume":"1\u20136","author":"DD Agoons","year":"2021","unstructured":"Agoons DD, Agoons BB, Emmanuel KE, Matawalle FA, Cunningham JM (2021) Association between electronic cigarette use and fragility fractures among US adults. Am J Med Open 1\u20136:100002","journal-title":"Am J Med Open"},{"key":"1588_CR183","doi-asserted-by":"publisher","first-page":"282","DOI":"10.9758\/cpn.2018.16.3.282","volume":"16","author":"TH Song","year":"2018","unstructured":"Song TH, Shim JC, Jung DU, Moon JJ, Jeon DW, Kim SJ, Oh MK (2018) Increased bone mineral density after abstinence in male patients with alcohol dependence. Clin Psychopharmacol Neurosci 16:282\u2013289","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1588_CR184","unstructured":"Department of Health (2016) UK chief medical officers\u2019 alcohol guidelines review summary of the proposed new guidelines. Williams Lea. https:\/\/assets.publishing.service.gov.uk\/media\/5a7f51b4e5274a2e87db5206\/summary.pdf"},{"key":"1588_CR185","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7326\/M14-0317","volume":"161","author":"CJ Crandall","year":"2014","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711\u2013723","journal-title":"Ann Intern Med"},{"key":"1588_CR186","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00198-025-07440-1","volume":"36","author":"C Beaudart","year":"2025","unstructured":"Beaudart C, Veronese N, Douxfils J et al (2025) Pth1 receptor agonists for fracture risk: a systematic review and network meta-analysis. Osteoporos Int 36:951\u2013967","journal-title":"Osteoporos Int"},{"key":"1588_CR187","first-page":"1535","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Interv Trial Res Group Lancet 348:1535\u20131541","journal-title":"Fracture Interv Trial Res Group Lancet"},{"key":"1588_CR188","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610","journal-title":"N Engl J Med"},{"key":"1588_CR189","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Glucocorticoid-induced osteoporosis intervention study group et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292\u2013299","journal-title":"N Engl J Med"},{"key":"1588_CR190","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1588_CR191","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"1588_CR192","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719\u2013725","journal-title":"J Bone Miner Res"},{"key":"1588_CR193","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277\u2013285","journal-title":"Calcif Tissue Int"},{"key":"1588_CR194","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res 15:1006\u20131013","journal-title":"J Bone Miner Res"},{"key":"1588_CR195","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","volume":"15","author":"PD Delmas","year":"2004","unstructured":"Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792\u2013798","journal-title":"Osteoporos Int"},{"key":"1588_CR196","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1588_CR197","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"1588_CR198","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S et al (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"1588_CR199","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1588_CR200","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714\u20131723","journal-title":"N Engl J Med"},{"key":"1588_CR201","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253\u20131263","journal-title":"Lancet"},{"key":"1588_CR202","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jbmr.3860","volume":"35","author":"IR Reid","year":"2020","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD (2020) Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res 35:20\u201327","journal-title":"J Bone Miner Res"},{"key":"1588_CR203","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380\u20134387","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR204","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445\u2013454","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1588_CR205","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"1588_CR206","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1588_CR207","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbjaerg CS, Ho PR et al (2015) A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 100:1335\u20131342","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR208","unstructured":"(2014) https:\/\/www.gov.uk\/drug-safety-update\/denosumab-monitoring-recommended Accessed January 7th 2021"},{"key":"1588_CR209","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR210","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2010-1805","volume":"96","author":"PD Miller","year":"2011","unstructured":"Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394\u2013402","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR211","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR212","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"1588_CR213","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00198-019-05002-w","volume":"30","author":"EM Dennison","year":"2019","unstructured":"Dennison EM, Cooper C, Kanis JA, Bruy\u00e8re O, Silverman S, McCloskey E, Abrahamsen B, Prieto-Alhambra D, Ferrari S (2019) Fracture risk following intermission of osteoporosis therapy. Osteoporos Int 30:1733\u20131743","journal-title":"Osteoporos Int"},{"key":"1588_CR214","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101:371\u2013374","journal-title":"Calcif Tissue Int"},{"key":"1588_CR215","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00223-019-00553-w","volume":"105","author":"AM Horne","year":"2019","unstructured":"Horne AM, Mihov B, Reid IR (2019) Effect of zoledronate on bone loss after romosozumab\/denosumab: 2-year follow-up. Calcif Tissue Int 105:107\u2013108","journal-title":"Calcif Tissue Int"},{"key":"1588_CR216","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Mineral Res 34:2220\u20132228","journal-title":"J Bone Mineral Res"},{"key":"1588_CR217","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res 35:1207\u20131215","journal-title":"J Bone Miner Res"},{"key":"1588_CR218","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35:1858\u20131870","journal-title":"J Bone Miner Res"},{"key":"1588_CR219","doi-asserted-by":"publisher","first-page":"e4155\u2013e4162","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155\u2013e4162","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR220","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"key":"1588_CR221","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","volume":"105","author":"D Kendler","year":"2020","unstructured":"Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, Huang S, Stad RK (2020) Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 105:e255-264","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1588_CR222","doi-asserted-by":"publisher","first-page":"CD004143","DOI":"10.1002\/14651858.CD004143.pub5","volume":"1","author":"J Marjoribanks","year":"2012","unstructured":"Marjoribanks J, Farquhar C, Roberts H, Lethaby A (2012) Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 1(1):CD004143. https:\/\/doi.org\/10.1002\/14651858.CD004143.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"1588_CR223","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. JAMA 288:321\u2013333","journal-title":"JAMA"},{"key":"1588_CR224","unstructured":"National Institute for Health and Care Excellence (NICE) (2019) Menopause: diagnosis and management. NICE guideline [NG23]. https:\/\/www.nice.org.uk\/guidance\/ng23"},{"key":"1588_CR225","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","volume":"142","author":"SR El Khoudary","year":"2020","unstructured":"El Khoudary SR, Aggarwal B, Beckie TM et al (2020) Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation 142:e506\u2013e532","journal-title":"Circulation"},{"key":"1588_CR226","unstructured":"Medicines and Healthcare products Regulatory Agency (2019) Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping. https:\/\/www.gov.uk\/drug-safetyupdate\/hormone-replacement-therapy-hrt-further-information-on-the-known-increased-risk-of-breast-cancer-with-hrt-and-itspersistence-after-stopping"},{"key":"1588_CR227","unstructured":"Society BM (2024) Consensus statement: the benefits and risks of HRT before and after a breast cancer diagnosis. https:\/\/thebms.org.uk\/wp-content\/uploads\/2024\/04\/08-BMS-ConsensusStatement-Benefits-risks-of-HRT-before-after-a-breast-cancer-diagnosis-MARCH2024-A.pdf"},{"key":"1588_CR228","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/0003-4819-113-9-649","volume":"113","author":"JC Gallagher","year":"1990","unstructured":"Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113:649\u2013655","journal-title":"Ann Intern Med"},{"key":"1588_CR229","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) Investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"1588_CR230","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.amjmed.2009.01.033","volume":"122","author":"E Barrett-Connor","year":"2009","unstructured":"Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D (2009) Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med 122:754\u2013761","journal-title":"Am J Med"},{"key":"1588_CR231","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart Trial I (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125\u2013137","journal-title":"N Engl J Med"},{"key":"1588_CR232","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"1588_CR233","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR234","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1210\/jc.2012-3048","volume":"98","author":"JM Kaufman","year":"2013","unstructured":"Kaufman JM, Audran M, Bianchi G et al (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98:592\u2013601","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR235","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2165\/11533770-000000000-00000","volume":"33","author":"V Osborne","year":"2010","unstructured":"Osborne V, Layton D, Perrio M, Wilton L, Shakir SA (2010) Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf 33:579\u2013591","journal-title":"Drug Saf"},{"key":"1588_CR236","unstructured":"European Medicines Agency (2013) Recommendation to restrict the use of Protelos \/ Osseor (strontium ranelate). European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/news\/recommendation-restrict-use-protelos-osseor-strontium-ranelate"},{"key":"1588_CR237","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1359\/jbmr.090601","volume":"24","author":"GM Blake","year":"2009","unstructured":"Blake GM, Compston JE, Fogelman I (2009) Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Miner Res 24:1354\u20131357","journal-title":"J Bone Miner Res"},{"key":"1588_CR238","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"1588_CR239","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","volume":"120","author":"A Diez-Perez","year":"2019","unstructured":"Diez-Perez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodriguez M (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1\u20138","journal-title":"Bone"},{"key":"1588_CR240","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, Davis S (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone 130:115081","journal-title":"Bone"},{"key":"1588_CR241","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317","journal-title":"J Bone Miner Res"},{"key":"1588_CR242","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346\u20133355","journal-title":"Arthritis Rheum"},{"key":"1588_CR243","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623\u20131630","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR244","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"JY Reginster","year":"2019","unstructured":"Reginster JY, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA (2019) Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 30:1465\u20131473","journal-title":"Osteoporos Int"},{"key":"1588_CR245","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR246","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30:2437\u20132448","journal-title":"Osteoporos Int"},{"key":"1588_CR247","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129\u20132134","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR248","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155","journal-title":"Lancet"},{"key":"1588_CR249","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219\u20131226","journal-title":"J Bone Miner Res"},{"key":"1588_CR250","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397\u20131406. https:\/\/doi.org\/10.1002\/jbmr.3452","journal-title":"J Bone Miner Res"},{"key":"1588_CR251","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Research 34:419\u2013428","journal-title":"J Bone Miner Research"},{"key":"1588_CR252","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949\u20132957","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR253","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"1588_CR254","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/jbmr.3176","volume":"32","author":"TM Keaveny","year":"2017","unstructured":"Keaveny TM, Crittenden DB, Bolognese MA et al (2017) Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Research 32:1956\u20131962","journal-title":"J Bone Miner Research"},{"key":"1588_CR255","doi-asserted-by":"publisher","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H et al (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574","journal-title":"Bone"},{"key":"1588_CR256","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00198-018-4791-3","volume":"30","author":"S Nayak","year":"2019","unstructured":"Nayak S, Greenspan SL (2019) A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int 30:705\u2013720","journal-title":"Osteoporos Int"},{"key":"1588_CR257","unstructured":"National Institute for Health and Care Excellence (2016) Multimorbidity: clinical assessment and management. NICE guideline [NG56]. https:\/\/www.nice.org.uk\/guidance\/ng56"},{"key":"1588_CR258","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Research 31:16\u201335","journal-title":"J Bone Miner Research"},{"key":"1588_CR259","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/M19-0533","volume":"171","author":"HA Fink","year":"2019","unstructured":"Fink HA, MacDonald R, Forte ML et al (2019) Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med 171:37\u201350","journal-title":"Ann Intern Med"},{"key":"1588_CR260","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1359\/JBMR.040326","volume":"19","author":"KE Ensrud","year":"2004","unstructured":"Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture intervention trial long-term extension. J Bone Min Res 19:1259\u20131269","journal-title":"J Bone Min Res"},{"key":"1588_CR261","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"1588_CR262","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S8756-3282(98)00044-1","volume":"22","author":"P Ravn","year":"1998","unstructured":"Ravn P, Christensen JO, Baumann M, Clemmesen B (1998) Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 22:559\u2013564","journal-title":"Bone"},{"key":"1588_CR263","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"NB Watts","year":"2008","unstructured":"Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365\u2013372","journal-title":"Osteoporos Int"},{"key":"1588_CR264","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Mineral Research 27:243\u2013254","journal-title":"J Bone Mineral Research"},{"key":"1588_CR265","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/jbmr.3654","volume":"34","author":"TY Kim","year":"2019","unstructured":"Kim TY, Bauer DC, McNabb BL, Schafer AL, Cosman F, Black DM, Eastell R (2019) Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials. J Bone Miner Res 34:810\u2013816","journal-title":"J Bone Miner Res"},{"key":"1588_CR266","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","volume":"174","author":"DC Bauer","year":"2014","unstructured":"Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med 174:1126\u20131134","journal-title":"JAMA Intern Med"},{"key":"1588_CR267","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"1588_CR268","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"1588_CR269","unstructured":"Scottish Dental Clinical Effectiveness Programme (2017) Oral health management of patients at risk of medication-related osteonecrosis of the jaw: dental clinical guidance. https:\/\/www.sdcep.org.uk\/wp-content\/uploads\/2017\/04\/SDCEP-Oral-Health-Management-of-Patients-at-Risk-of-MRONJ-Guidance-full.pdf"},{"key":"1588_CR270","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/MAO.0b013e31827ca34d","volume":"34","author":"R Salzman","year":"2013","unstructured":"Salzman R, Hoza J, Perina V, St\u00e1rek I (2013) Osteonecrosis of the external auditory canal associated with oral bisphosphonate therapy: case report and literature review. Otol Neurotol 34:209\u2013213","journal-title":"Otol Neurotol"},{"key":"1588_CR271","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1210\/er.2018-00001","volume":"40","author":"DM Black","year":"2019","unstructured":"Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N (2019) Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev 40:333\u2013368","journal-title":"Endocr Rev"},{"key":"1588_CR272","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Min Research 25:2267\u20132294","journal-title":"J Bone Min Research"},{"key":"1588_CR273","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"1588_CR274","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.1893","volume":"28","author":"L Gedmintas","year":"2013","unstructured":"Gedmintas L, Solomon DH, Kim SC (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28:1729\u20131737","journal-title":"J Bone Miner Res"},{"key":"1588_CR275","doi-asserted-by":"publisher","first-page":"i3365","DOI":"10.1136\/bmj.i3365","volume":"353","author":"B Abrahamsen","year":"2016","unstructured":"Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353:i3365","journal-title":"BMJ"},{"key":"1588_CR276","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","volume":"105","author":"DM van de Laarschot","year":"2020","unstructured":"van de Laarschot DM, McKenna MJ, Abrahamsen B, Langdahl B, Cohen-Solal M, Gua\u00f1abens N, Eastell R, Ralston SH, Zillikens MC (2020) Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society. J Clin Endocrin Metab 105:1682\u20131699","journal-title":"J Clin Endocrin Metab"},{"key":"1588_CR277","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jocd.2018.03.009","volume":"22","author":"M Carter","year":"2019","unstructured":"Carter M (2019) Prevention of glucocorticoid-induced osteoporosis: clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. J Clin Densitom 22:25\u201330","journal-title":"J Clin Densitom"},{"key":"1588_CR278","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777\u2013787","journal-title":"Osteoporos Int"},{"key":"1588_CR279","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202\u2013211","journal-title":"Arthritis Rheum"},{"key":"1588_CR280","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309\u20132318","journal-title":"Arthritis Rheum"},{"key":"1588_CR281","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa228","author":"J Deng","year":"2020","unstructured":"Deng J, Silver Z, Huang E, Zheng E, Kavanagh K, Wen A, Cheng W, Dobransky J, Sanger S, Grammatopoulos G (2020) Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keaa228","journal-title":"Rheumatology (Oxford)"},{"key":"1588_CR282","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jbo.2020.100311","volume":"25","author":"JE Brown","year":"2020","unstructured":"Brown JE, Handforth C, Compston JE et al (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss A consensus position statement from an expert group. J Bone Oncol 25:100311","journal-title":"J Bone Oncol"},{"key":"1588_CR283","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2011-3045","volume":"97","author":"NB Watts","year":"2012","unstructured":"Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS, Endocrine S (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:1802\u20131822","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR284","unstructured":"Adler Robert A (2024) Osteoporosis in men. Endotext. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558007\/"},{"key":"1588_CR285","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656\u20133661","journal-title":"J Clin Endocrinol Metab"},{"key":"1588_CR286","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164","journal-title":"N Engl J Med"},{"key":"1588_CR287","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.euo.2018.11.001","volume":"2","author":"JS Joseph","year":"2019","unstructured":"Joseph JS, Lam V, Patel MI (2019) Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 2:551\u2013561","journal-title":"Eur Urol Oncol"},{"key":"1588_CR288","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bju.14015","volume":"121","author":"Y Poon","year":"2018","unstructured":"Poon Y, Pechlivanoglou P, Alibhai SMH, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M (2018) Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 121:17\u201328","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"1588_CR289","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","volume":"34","author":"DM Reid","year":"2008","unstructured":"Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 34(Suppl 1):S3-18","journal-title":"Cancer Treat Rev"},{"key":"1588_CR290","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ et al (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312","journal-title":"J Bone Oncol"},{"key":"1588_CR291","unstructured":"National Institute for Health and Care Excellence (NICE) (2017) Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates [ES15]. https:\/\/www.nice.org.uk\/advice\/es15"},{"key":"1588_CR292","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC (2021) Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 28:100355","journal-title":"J Bone Oncol"},{"key":"1588_CR293","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-020-05640-3","volume":"181","author":"H Miyashita","year":"2020","unstructured":"Miyashita H, Satoi S, Kuno T, Cruz C, Malamud S, Kim SM (2020) Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat 181:279\u2013289","journal-title":"Breast Cancer Res Treat"},{"key":"1588_CR294","volume-title":"Traitement de la douleur canc\u00e9reuse","author":"World Health Organization","year":"1987","unstructured":"World Health Organization (1987) Traitement de la douleur canc\u00e9reuse. Organisation mondiale de la Sant\u00e9, Gen\u00e8ve"},{"key":"1588_CR295","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/ageing\/afx192","volume":"47","author":"P Schofield","year":"2018","unstructured":"Schofield P (2018) The assessment of pain in older people: UK national guidelines. Age Ageing 47:i1\u2013i22","journal-title":"Age Ageing"},{"key":"1588_CR296","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/ageing\/afs200","volume":"42","author":"British Geriatric Society","year":"2013","unstructured":"British Geriatric Society (2013) Guidance on the management of pain in older people. Age Ageing 42:i1\u2013i57","journal-title":"Age Ageing"},{"key":"1588_CR297","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00198-011-1676-0","volume":"23","author":"JA Knopp-Sihota","year":"2012","unstructured":"Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D (2012) Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 23:17\u201338","journal-title":"Osteoporos Int"},{"key":"1588_CR298","unstructured":"European Medicines Agency (2012) European Medicines Agency recommends limiting long-term use of calcitonin medicines. https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-limiting-long-term-use-calcitonin-medicines"},{"key":"1588_CR299","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00198-006-0169-z","volume":"17","author":"T Armingeat","year":"2006","unstructured":"Armingeat T, Brondino R, Pham T, Legr\u00e9 V, Lafforgue P (2006) Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 17:1659\u20131665","journal-title":"Osteoporos Int"},{"issue":"7","key":"1588_CR300","doi-asserted-by":"publisher","first-page":"CD008618","DOI":"10.1002\/14651858.CD008618.pub3","volume":"7","author":"JC Gibbs","year":"2019","unstructured":"Gibbs JC, MacIntyre NJ, Ponzano M, Templeton JA, Thabane L, Papaioannou A, Giangregorio LM (2019) Exercise for improving outcomes after osteoporotic vertebral fracture. Cochrane Database Syst Rev 7(7):CD008618. https:\/\/doi.org\/10.1002\/14651858.CD008618.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1588_CR301","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.3653","volume":"34","author":"PR Ebeling","year":"2019","unstructured":"Ebeling PR, Akesson K, Bauer DC et al (2019) The efficacy and safety of vertebral augmentation: a second ASBMR task force report. J Bone Miner Res 34:3\u201321. https:\/\/doi.org\/10.1002\/jbmr.3653","journal-title":"J Bone Miner Res"},{"key":"1588_CR302","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00198-017-4099-8","volume":"28","author":"HK Svensson","year":"2017","unstructured":"Svensson HK, Olsson LE, Hansson T, Karlsson J, Hansson-Olofsson E (2017) The effects of person-centered or other supportive interventions in older women with osteoporotic vertebral compression fractures-a systematic review of the literature. Osteoporos Int 28:2521\u20132540","journal-title":"Osteoporos Int"},{"key":"1588_CR303","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/j.wneu.2020.05.199","volume":"141","author":"RC Hofler","year":"2020","unstructured":"Hofler RC, Jones GA (2020) Bracing for acute and subacute osteoporotic compression fractures: a systematic review of the literature. World Neurosurg 141:e453\u2013e460","journal-title":"World Neurosurg"},{"key":"1588_CR304","first-page":"Cd006349","volume":"11","author":"R Buchbinder","year":"2018","unstructured":"Buchbinder R, Johnston RV, Rischin KJ, Homik J, Jones CA, Golmohammadi K, Kallmes DF (2018) Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. Cochrane Database Syst Rev 11:Cd006349","journal-title":"Cochrane Database Syst Rev"},{"key":"1588_CR305","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00198-007-0391-3","volume":"18","author":"A Zambito","year":"2007","unstructured":"Zambito A, Bianchini D, Gatti D, Rossini M, Adami S, Viapiana O (2007) Interferential and horizontal therapies in chronic low back pain due to multiple vertebral fractures: a randomized, double blind, clinical study. Osteoporos Int 18:1541\u20131545","journal-title":"Osteoporos Int"},{"key":"1588_CR306","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/jbmr.3990","volume":"35","author":"KF Axelsson","year":"2020","unstructured":"Axelsson KF, Johansson H, Lundh D, M\u00f6ller M, Lorentzon M (2020) Association between recurrent fracture risk and implementation of fracture liaison services in four Swedish hospitals: a cohort study. J Bone Miner Res 35:1216\u20131223","journal-title":"J Bone Miner Res"},{"key":"1588_CR307","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bone.2018.03.018","volume":"111","author":"CH Wu","year":"2018","unstructured":"Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S, Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone 111:92\u2013100","journal-title":"Bone"},{"key":"1588_CR308","unstructured":"Department of Health (2009) Fracture prevention services - an economic evaluation. https:\/\/data.parliament.uk\/DepositedPapers\/Files\/DEP2011-0324\/DEP2011-0324.pdf"},{"key":"1588_CR309","unstructured":"NHS_RightCare (2017) Falls and fragility fractures pathway. https:\/\/www.england.nhs.uk\/rightcare\/products\/pathways\/falls-and-fragility-fractures-pathway\/"},{"key":"1588_CR310","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00198-015-3192-0","volume":"26","author":"MK Javaid","year":"2015","unstructured":"Javaid MK, Kyer C, Mitchell PJ et al (2015) Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF capture the fracture(R) best practice framework tool. Osteoporos Int 26:2573\u20132578","journal-title":"Osteoporos Int"},{"key":"1588_CR311","unstructured":"Royal Osteoporosis Society (2019) Effective secondary prevention of fragility fractures: clinical standards for fracture liaison services https:\/\/theros.org.uk\/media\/1eubz33w\/ros-clinical-standards-for-fracture-liaison-services-august-2019.pdf"},{"key":"1588_CR312","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00198-012-2090-y","volume":"24","author":"K Ganda","year":"2013","unstructured":"Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, Eisman JA, March L, Seibel MJ (2013) Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int 24:393\u2013406","journal-title":"Osteoporos Int"},{"key":"1588_CR313","doi-asserted-by":"crossref","unstructured":"Ganda K, Mitchell PJ, Seibel MJ (2019) Chapter 3, models of secondary fracture prevention: systematic review and meta analysis of outcomes. In: Seibel MJ, Mitchell PJ (ed) Secondary Fracture Prevention an International Perspective, Elsevier Inc, pp 33\u201362","DOI":"10.1016\/B978-0-12-813136-7.00003-X"},{"key":"1588_CR314","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00198-017-4370-z","volume":"29","author":"CH Wu","year":"2018","unstructured":"Wu CH, Chen CH, Chen PH, Yang JJ, Chang PC, Huang TC, Bagga S, Sharma Y, Lin RM, Chan DC (2018) Identifying characteristics of an effective fracture liaison service: systematic literature review. Osteoporos Int 29:1023\u20131047","journal-title":"Osteoporos Int"},{"key":"1588_CR315","unstructured":"Public Health England (2017) Falls and fracture consensus statement: supporting commissioning for prevention Public Health England with the National Falls Prevention Coordination Group,http:\/\/www.gov.uk\/phe"},{"key":"1588_CR316","unstructured":"Royal Osteoporosis Society (2017) Clinical guidance for the effective identification of vertebral fractures https:\/\/theros.org.uk\/healthcare-professionals\/tools-and-resources\/clinical-guidance\/"},{"key":"1588_CR317","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-021-00913-w","volume":"16","author":"L Bullock","year":"2021","unstructured":"Bullock L, Crawford-Manning F, Cottrell E et al (2021) Developing a model fracture liaison service consultation with patients, carers and clinicians: a Delphi survey to inform content of the iFraP complex consultation intervention. Arch Osteoporos 16:58","journal-title":"Arch Osteoporos"},{"key":"1588_CR318","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00198-020-05479-w","volume":"31","author":"Z Paskins","year":"2020","unstructured":"Paskins Z, Torres Roldan VD, Hawarden AW et al (2020) Quality and effectiveness of osteoporosis treatment decision aids: a systematic review and environmental scan. Osteoporos Int 31:1837\u20131851","journal-title":"Osteoporos Int"},{"key":"1588_CR319","unstructured":"National Institute for Health and Care Excellence (2009) Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guideline [CG76]. https:\/\/www.nice.org.uk\/guidance\/cg76"},{"key":"1588_CR320","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-020-05378-0","volume":"31","author":"D Cornelissen","year":"2020","unstructured":"Cornelissen D, de Kunder S, Si L, Reginster JY, Evers S, Boonen A, Hiligsmann M (2020) Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 31:1645\u20131669","journal-title":"Osteoporos Int"},{"key":"1588_CR321","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-020-05308-0","volume":"31","author":"J Martin","year":"2020","unstructured":"Martin J, Viprey M, Castagne B, Merle B, Giroudon C, Chapurlat R, Schott AM (2020) Interventions to improve osteoporosis care: a systematic review and meta-analysis. Osteoporos Int 31:429\u2013446","journal-title":"Osteoporos Int"},{"key":"1588_CR322","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00198-020-05435-8","volume":"31","author":"MA Clynes","year":"2020","unstructured":"Clynes MA, Westbury LD, Dennison EM, Kanis JA, Javaid MK, Harvey NC, Fujita M, Cooper C, Leslie WD, Shuhart CR (2020) Bone densitometry worldwide: a global survey by the ISCD and IOF. Osteoporos Int 31:1779\u20131786","journal-title":"Osteoporos Int"},{"key":"1588_CR323","unstructured":"The Health Foundation (2021) Quality improvement made simple: what everyone should know about health care quality improvement, 3rd edn. The Health Foundation, 8 Salisbury Square, London"},{"key":"1588_CR324","doi-asserted-by":"publisher","unstructured":"Javaid MK, Harvey NC, McCloskey E, Kanis JA, C C (2021) Assessment and management of imminent fracture risk in the setting of the fracture liaison service. Osteo Internat in press:\u00a0https:\/\/doi.org\/10.1007\/s00198-021-06284-9","DOI":"10.1007\/s00198-021-06284-9"},{"key":"1588_CR325","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467\u2013475","journal-title":"Bone"},{"key":"1588_CR326","unstructured":"International Society for Clinical Densitometry (ISCD) (2019) Adult official positions of the ISCD. https:\/\/iscd.org\/learn\/official-positions\/adult-positions\/"},{"key":"1588_CR327","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD et al (2013) Grade guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66:719\u2013725","journal-title":"J Clin Epidemiol"},{"key":"1588_CR328","doi-asserted-by":"publisher","first-page":"a744","DOI":"10.1136\/bmj.a744","volume":"337","author":"R Jaeschke","year":"2008","unstructured":"Jaeschke R, Guyatt GH, Dellinger P, Sch\u00fcnemann H, Levy MM, Kunz R, Norris S, Bion J (2008) Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 337:a744","journal-title":"BMJ"},{"key":"1588_CR329","unstructured":"National Institute for Health and Care Excellence (NICE) (2012) The guidelines manual. NICE process and methods [PMG6]. Section 9 Developing and wording guideline recommendations. https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/developing-and-wording-guideline-recommendations"},{"key":"1588_CR330","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1001\/jama.2017.16952","volume":"318","author":"G Gartlehner","year":"2017","unstructured":"Gartlehner G, Patel SV, Feltner C, Weber RP, Long R, Mullican K, Boland E, Lux L, Viswanathan M (2017) Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. JAMA 318:2234\u20132249","journal-title":"JAMA"},{"key":"1588_CR331","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/jgs.14668","volume":"65","author":"S Nayak","year":"2017","unstructured":"Nayak S, Greenspan SL (2017) Osteoporosis treatment efficacy for men: a systematic review and meta-analysis. J Am Geriatr Soc 65:490\u2013495","journal-title":"J Am Geriatr Soc"},{"key":"1588_CR332","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3389\/fphar.2019.00882","volume":"10","author":"LF Zeng","year":"2019","unstructured":"Zeng LF, Pan BQ, Liang GH et al (2019) Does routine anti-osteoporosis medication lower the risk of fractures in male subjects? An updated systematic review with meta-analysis of clinical trials. Front Pharmacol 10:882","journal-title":"Front Pharmacol"},{"key":"1588_CR333","doi-asserted-by":"publisher","first-page":"e12691","DOI":"10.1097\/MD.0000000000012691","volume":"97","author":"YK Wang","year":"2018","unstructured":"Wang YK, Zhang YM, Qin SQ, Wang X, Ma T, Guo JB, Zhu C, Luo ZJ (2018) Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 97:e12691","journal-title":"Medicine (Baltimore)"},{"key":"1588_CR334","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2147\/DDDT.S148654","volume":"13","author":"ZA Yanbeiy","year":"2019","unstructured":"Yanbeiy ZA, Hansen KE (2019) Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther 13:2843\u20132852","journal-title":"Drug Des Devel Ther"},{"key":"1588_CR335","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05479-w","author":"Z Paskins","year":"2020","unstructured":"Paskins Z, Torres Roldan VD, Hawarden AW et al (2020) Quality and effectiveness of osteoporosis treatment decision aids: a systematic review and environmental scan. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-020-05479-w","journal-title":"Osteoporos Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01588-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T22:01:47Z","timestamp":1766527307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01588-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":335,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01588-3","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The National Osteoporosis Guideline Group (NOGG) Guideline Writing Group is divided into two groups, a Guideline Development Group (GDG) and an Expert Advisory Group (EAG). The GDG consists of eight voting members (CLG, JC, JE, JK, RL, SL, ZP, JT), and three lay members (JB, JP, NV). One member has a financial disclosure, unrelated to drug development (JC received honoraria for speaking at a CME approved bone academy meeting and for consultancy relating to the characterisation of people at very high fracture risk), and the remaining ten have no financial disclosures. ZP is funded by the National Institute for Health Research (NIHR) (Clinician Scientist Award (CS-2018\u201318-ST2-010)\/NIHR Academy). ZP has undertaken consultancy for non-promotional activities for UCB. One member (JK) is also a member of the FRAX group; hence, all FRAX-based recommendations had to be agreed by consensus of all the GDG. The Chair (CLG) has no disclosures; she is funded by the National Institute for Health and Care Research (NIHR302394). The EAG is composed of nine members; all of whom have relevant conflicts of interest. DA has received advisory\/speaking fees from UCB and Internis Pharma. CC has received advisory\/speaking fees from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestle, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. NG is on the advisory board of UCB, Novo Nordisk, and Shire\/Takeda and has received fees from UCB and Takeda. NCH has received advisory board\/consultancy fees\/honoraria from Alliance for Better Bone Health, A mgen, MSD, Eli Lilly, UCB, Radius, Servier, Shire, Consilient Healthcare and Internis Pharma. EMC has received advisory\/honoraria from A mgen, Consilient Healthcare, Kyowa Kirin, Eli Lilly, Fresenius Kabi, Internis, ObsEva, Radius Inc and Redx Pharma and received research funding from A mgen, Internis, and Radius Inc. KM has received conference sponsorship from Abbvie, Alexion, UCB, Novartis, Kyowa Kirin, Lilly, Pfizer and Internis and advisory\/honoraria from Alexion and UCB. KP received advisory\/speaker fees from UCB, which were then donated to charities. DR has received advisory fees from UCB, Theramex and Osteolabs. MS has received advisory\/speaker fees from UCB, and speaker fees from A mgen and Gedeon Richter. All members of the GDG and EAG have read NICE\u2019s \u2018Policy on declaring and managing interests for NICE advisory boards\u2019 (version 1.1, July 2019). Disclosures of all members of both groups are available on the NOGG website. Both the GDG and the EAG attend online meetings and take part in email discussions. However, voting on the recommendations is restricted to the GDG. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"119"}}